Time filter

Source Type

PubMed | International Medical University, South China University of Technology and c State Key Laboratory of Antibody Medicine and Targeted Therapy
Type: Journal Article | Journal: mAbs | Year: 2016

Nivolumab, an anti-programmed death (PD)1 IgG4 antibody, has shown notable success as a cancer treatment. Here, we report that nivolumab was susceptible to aggregation during manufacturing, particularly in routine purification steps. Our experimental results showed that exposure to low pH caused aggregation of nivolumab, and the Fc was primarily responsible for an acid-induced unfolding phenomenon. To compare the intrinsic propensity of acid-induced aggregation for other IgGs subclasses, tocilizumab (IgG1), panitumumab (IgG2) and atezolizumab (aglyco-IgG1) were also investigated. The accurate pH threshold of acid-induced aggregation for individual IgG Fc subclasses was identified and ranked as: IgG1

Loading c State Key Laboratory of Antibody Medicine and Targeted Therapy collaborators
Loading c State Key Laboratory of Antibody Medicine and Targeted Therapy collaborators